Direct-acting antivirals for pediatric chronic hepatitis C virus infection
CADTH
Record ID 32018005327
English
Authors' objectives:
What is the clinical effectiveness of GLE-PIB for the treatment of chronic HCV infection in pediatric patients?What is the clinical effectiveness of SOF-VEL for the treatment of chronic HCV infection in pediatric patients?What is the cost-effectiveness of GLE-PIB for the treatment of chronic HCV infection in pediatric patients?What is the cost-effectiveness of SOF-VEL for the treatment of chronic HCV infection in pediatric patients?
Authors' results and conclusions:
Clinical evidence showed that treatment with glecaprevir-pibrentasvir for children and adolescents with chronic hepatitis C virus infection was efficacious with an overall sustained virologic response 12 weeks after treatment near 100%.
Glecaprevir-pibrentasvir treatment was well-tolerated as there were no serious adverse events or adverse events leading to treatment discontinuation. Most adverse events were mild.
We did not find any studies that evaluated the cost-effectiveness of glecaprevir-pibrentasvir for the treatment of chronic hepatitis C virus infection in pediatric patients.
We did not find any peer-reviewed studies that evaluated the clinical effectiveness of sofosbuvir-velpatasvir for the treatment of chronic hepatitis C virus infection in pediatric patients. Unpublished data in a conference abstract and clinical trial registry suggest effectiveness of sofosbuvir-velpatasvir, but the findings should be interpreted with cautions.
We did not find any studies that evaluated the cost-effectiveness of sofosbuvir-velpatasvir for the treatment of chronic hepatitis C virus infection in pediatric patients.
Details
Project Status:
Completed
URL for project:
https://www.cadth.ca/direct-acting-antivirals-pediatric-chronic-hepatitis-c-virus-infection
Year Published:
2023
URL for published report:
https://www.cadth.ca/direct-acting-antivirals-pediatric-chronic-hepatitis-c-virus-infection
English language abstract:
An English language summary is available
Publication Type:
Rapid Review
Country:
Canada
MeSH Terms
- Hepatitis C
- Hepatitis C, Chronic
- Child
- Antiviral Agents
- Hepacivirus
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
<p>Canadian Agency for Drugs and Technologies in Health (CADTH)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.